akn
Musclechemistry Member
Androgenic 91
Anabolic 1100
Standard Methyltestosterone (oral)
Chemical Name 2alpha,3alpha-epithio-17alpha-methylSalpha-
androstan-17beta-ol
Estrogenic Activity none
Progestational Activity none
Description:
Methepitiostane is an oral anabolic steroid derived from
dihydrotestosterone. This agent is a c17-alpha alkylated
analog of epitiostane (see Thioderon), and like this drug
also displays a favorable balance between anabolic and
androgenic effect. In this case, however, the separation is
considerably more pronounced, with the drug exhibiting
an anabolic effect that is roughly 12 times more
pronounced than its androgenic effect.That is according to
the standard animal assays, which often vary somewhat to
experiences in humans. This drug was never clinical tested
in humans, so what is known of it is based on a small
number of animal experiments, and structural and
anecdotal observations. What can be stated with certainty
if that methepitiostane is a primarily anabolic steroid with
a pronounced level of activity, and is effective for the
promotion of lean mass and strength gains. It likely also
imparts some anti-estrogenic effect, further strengthening
the association between this agent and dieting, cutting,
and lean muscle mass phases of training as opposed to
bulking.
History:
Methepitiostane was first described in 1966, during
investigations into a series of A-ring modified androstane
derivatives.571 That same year it was assayed for anabolic
and androgenic potency via the standard rat assays, and
demonstrated both pronounced anabolic properties and
very weak relative androgenicity.572 The assay results were
probably most similar to desoxymethyltestosterone
(Madol), although methepitiostane is about half as
androgenic. Although the results of the early testing were
very favorable, this agent never progressed to the point of
being a commercial steroid product or even tested on
human subjects. Like a great many steroids, it was
examined but not actualized as a prescription product. For
forty years, the agent would be lost to the public, existing
as an item of research interest only.
Methepitiostane would emerge from research obscurity at
the end of 2006, when a new company called Recomp
Performance Nutrition introduced it to the U.S. market
under the trade name Havoc. It would be sold openly as a
dietary supplement.This channel of sales does not reflect a
weak potency or "non-steroid" classification, however, as
methepitiostane is very much a potent drug. It is being
sold as such due to the fact that the U.s. dietary
supplement market is not tightly regulated, and the drug
was never classified (specifically according to the law) as an
anabolic steroid. While regulations do exist that would
prevent the sale of an unapproved new drug as a food
supplement, they do not carry the same weight as the
anabolic steroid laws, and have historically not been
aggressively enforced. Methepitiostane remains on sale as
of December 2006, although the manufacturer has stated
that they plan to discontinue the product very shortly.
How Supplied:
Methepitiostane was never approved as a prescription
drug preparation. It is being sold in the U.S. supplement
market under the trade name Havoc, and is supplied in the
form of capsules containing 10 mg of steroid.
Structural Characteristics:
Methepitiostane is a modified form of
dihydrotestosterone. It differs by 1) the addition of a 17alpha
methyl group, which helps protect the steroid from
metabolism during oral administration, and 2) the
replacement of 3-keto with 2,3alpha-epithio, which
increases anabolic strength while reducing relative
androgenicity.
Side Effects (Estrogenic):
Methepitiostane is not aromatized by the body, and is not
measurably estrogenic. Furthermore, its non-methylated
analog mepitiostane (Thioderon) is used clinically for its
inherent antiestrogenic effect. Some level of antiestrogenic effect is also assumed with methepitiostane. An antiestrogen
is, likewise, not necessary when using this
steroid, as gynecomastia should not be a concern even
among sensitive individuals. Since estrogen is the usual
culprit with water retention, this steroid instead produces
a lean, quality look to the physique with no fear of excess
subcutaneous fluid retention. This makes it a favorable
steroid to use during cutting cycles, when water and fat
retention are major concerns. Note that some users may
notice lethargy with this steroid, which may be due, in
part, to its low androgenic or estrogenic component.
Stacking it with an aromatizable androgen like
testosterone should alleviate this problem.
Side Effects (Androgenic):
Although classified as an anabolic steroid,androgenic side
effects are still possible with this substance, especially
with higher doses. This may include bouts of oily skin,
acne, and body/facial hair growth. Anabolic/androgenic
steroids may also aggravate male pattern hair loss.
Women are warned of the potential virilizing effects of
anabolic/androgenic steroids. These may include a
deepening of the voice, menstrual irregularities, changes
in skin texture, facial hair growth, and clitoral
enlargement. Methepitiostane is a steroid with very low
androgenic activity relative to its tissue-building actions,
making the threshold for strong androgenic side effects
comparably higher than with more androgenic agents
such as testosterone, methandrostenolone, or
fluoxymesterone. Note that methepitiostane is unaffected
by the 5-alpha reductase enzyme, so its relative
androgenicity is not affected by the concurrent use of
finasteride or dutasteride.
Side Effects (Hepatotoxicity):
Methepitiostane is a c17-alpha alkylated compound. This
alteration protects the drug from deactivation by the liver,
allowing a very high percentage of the drug entry into the
bloodstream following oral administration. e17-alpha
alkylated anabolic/androgenic steroids can be
hepatotoxic. Prolonged or high exposure may result in
liver damage. In rare instances life-threatening
dysfunction may develop. It is advisable to visit a
physician periodically during each cycle to monitor liver
function and overall health. Intake of c17-alpha alkylated
steroids is commonly limited to 6-8 weeks, in an effort to
avoid escalating liver strain.
The use of a liver detoxification supplement such as Liver
Stabil, Liv-52, or Essentiale Forte is advised while taking
any hepatotoxic anabolic/androgenic steroids.
Side Effects (Cardiovascular):
Anabolic/androgenic steroids can have deleterious effects
on serum cholesterol. This includes a tendency to reduce
HDL (good) cholesterol values and increase LDL (bad)
cholesterol values, which may shift the HDL to LDL
balance in a direction that favors greater risk of
arteriosclerosis. The relative impact of an
anabolic/androgenic steroid on serum lipids is dependant
on the dose, route of administration (oral vs. injectable),
type of steroid (aromatizable or non-aromatizable), and
level of resistance to hepatic metabolism.
Methepitiostane has a strong effect on the hepatic
management of cholesterol due to its structural resistance
to liver breakdown, non-aromatizable nature, and route of
administration. Anabolic/androgenic steroids may also
adversely affect blood pressure and triglycerides, reduce
endothelial relaxation, and support left ventricular
hypertrophy, all potentially increasing the risk of
cardiovascular disease and myocardial infarction.
To help reduce cardiovascular strain it is advised to
maintain an active cardiovascular exercise program and
minimize the intake of saturated fats, cholesterol, and
simple carbohydrates at all times during active AAS
administration. Supplementing with fish oils (4 grams per
day) and a natural cholesterol/antioxidant formula such as
Lipid Stabil or a product with comparable ingredients is
also recommended.
Side Effects (Testosterone Suppression):
All anabolic/androgenic steroids when taken in doses
sufficient to promote muscle gain are expected to
suppress endogenous testosterone production. Without
the intervention of testosterone stimulating substances,
testosterone levels should return to normal within 1-4
months of drug secession. Note that prolonged
hypogonadotrophic hypogonadism can develop
secondary to steroid abuse, necessitating medical
intervention.
The above side effects are not inclusive. For more detailed
discussion ofpotential side effects, see the Steroid Side Effects
section of this book.
Administration (Men):
Methepitiostane was never approved for use in humans.
Prescribing guidelines are unavailable. An effective
dosage for physique- or performance-enhancing
purposes falls in the range of 10-20 mg daily.This is usually
taken for no longer than 6-8 weeks, in an effort to avoid
significant liver strain. At this level the drug should impart
a measurable but moderate lean-mass-building effect,
which, depending on dietary and metabolic factors, may
be accompanied by measurable fat loss and an increase in
definition. Doses of 30 mg per day are also commonly
used, however given the high relative potency of the steroid may present significant hepatotoxicity. When
administered, higher doses are usually taken for durations
lasting no longer than 4-6 weeks.
Administration (Women):
Methepitiostane was never approved for use in humans.
Prescribing guidelines are unavailable. An effective
dosage for physique- or performance-enhancing
purposes would be around 5 mg per day. This would be
taken for no longer than 4-6 weeks, in an effort to avoid
significant liver strain or virilizing side effects. Given that
complete separation of anabolic and androgenic effect
has not been achieved with any steroid, this agent is still
capable of producing virilizing activity given the right
dose or individual sensitivity.
Availability:
Methepitiostane is currently only produced in U.S. as a
sports nutrition product, sold as Havoc and under
numerous other brand names.
Anabolic 1100
Standard Methyltestosterone (oral)
Chemical Name 2alpha,3alpha-epithio-17alpha-methylSalpha-
androstan-17beta-ol
Estrogenic Activity none
Progestational Activity none
Description:
Methepitiostane is an oral anabolic steroid derived from
dihydrotestosterone. This agent is a c17-alpha alkylated
analog of epitiostane (see Thioderon), and like this drug
also displays a favorable balance between anabolic and
androgenic effect. In this case, however, the separation is
considerably more pronounced, with the drug exhibiting
an anabolic effect that is roughly 12 times more
pronounced than its androgenic effect.That is according to
the standard animal assays, which often vary somewhat to
experiences in humans. This drug was never clinical tested
in humans, so what is known of it is based on a small
number of animal experiments, and structural and
anecdotal observations. What can be stated with certainty
if that methepitiostane is a primarily anabolic steroid with
a pronounced level of activity, and is effective for the
promotion of lean mass and strength gains. It likely also
imparts some anti-estrogenic effect, further strengthening
the association between this agent and dieting, cutting,
and lean muscle mass phases of training as opposed to
bulking.
History:
Methepitiostane was first described in 1966, during
investigations into a series of A-ring modified androstane
derivatives.571 That same year it was assayed for anabolic
and androgenic potency via the standard rat assays, and
demonstrated both pronounced anabolic properties and
very weak relative androgenicity.572 The assay results were
probably most similar to desoxymethyltestosterone
(Madol), although methepitiostane is about half as
androgenic. Although the results of the early testing were
very favorable, this agent never progressed to the point of
being a commercial steroid product or even tested on
human subjects. Like a great many steroids, it was
examined but not actualized as a prescription product. For
forty years, the agent would be lost to the public, existing
as an item of research interest only.
Methepitiostane would emerge from research obscurity at
the end of 2006, when a new company called Recomp
Performance Nutrition introduced it to the U.S. market
under the trade name Havoc. It would be sold openly as a
dietary supplement.This channel of sales does not reflect a
weak potency or "non-steroid" classification, however, as
methepitiostane is very much a potent drug. It is being
sold as such due to the fact that the U.s. dietary
supplement market is not tightly regulated, and the drug
was never classified (specifically according to the law) as an
anabolic steroid. While regulations do exist that would
prevent the sale of an unapproved new drug as a food
supplement, they do not carry the same weight as the
anabolic steroid laws, and have historically not been
aggressively enforced. Methepitiostane remains on sale as
of December 2006, although the manufacturer has stated
that they plan to discontinue the product very shortly.
How Supplied:
Methepitiostane was never approved as a prescription
drug preparation. It is being sold in the U.S. supplement
market under the trade name Havoc, and is supplied in the
form of capsules containing 10 mg of steroid.
Structural Characteristics:
Methepitiostane is a modified form of
dihydrotestosterone. It differs by 1) the addition of a 17alpha
methyl group, which helps protect the steroid from
metabolism during oral administration, and 2) the
replacement of 3-keto with 2,3alpha-epithio, which
increases anabolic strength while reducing relative
androgenicity.
Side Effects (Estrogenic):
Methepitiostane is not aromatized by the body, and is not
measurably estrogenic. Furthermore, its non-methylated
analog mepitiostane (Thioderon) is used clinically for its
inherent antiestrogenic effect. Some level of antiestrogenic effect is also assumed with methepitiostane. An antiestrogen
is, likewise, not necessary when using this
steroid, as gynecomastia should not be a concern even
among sensitive individuals. Since estrogen is the usual
culprit with water retention, this steroid instead produces
a lean, quality look to the physique with no fear of excess
subcutaneous fluid retention. This makes it a favorable
steroid to use during cutting cycles, when water and fat
retention are major concerns. Note that some users may
notice lethargy with this steroid, which may be due, in
part, to its low androgenic or estrogenic component.
Stacking it with an aromatizable androgen like
testosterone should alleviate this problem.
Side Effects (Androgenic):
Although classified as an anabolic steroid,androgenic side
effects are still possible with this substance, especially
with higher doses. This may include bouts of oily skin,
acne, and body/facial hair growth. Anabolic/androgenic
steroids may also aggravate male pattern hair loss.
Women are warned of the potential virilizing effects of
anabolic/androgenic steroids. These may include a
deepening of the voice, menstrual irregularities, changes
in skin texture, facial hair growth, and clitoral
enlargement. Methepitiostane is a steroid with very low
androgenic activity relative to its tissue-building actions,
making the threshold for strong androgenic side effects
comparably higher than with more androgenic agents
such as testosterone, methandrostenolone, or
fluoxymesterone. Note that methepitiostane is unaffected
by the 5-alpha reductase enzyme, so its relative
androgenicity is not affected by the concurrent use of
finasteride or dutasteride.
Side Effects (Hepatotoxicity):
Methepitiostane is a c17-alpha alkylated compound. This
alteration protects the drug from deactivation by the liver,
allowing a very high percentage of the drug entry into the
bloodstream following oral administration. e17-alpha
alkylated anabolic/androgenic steroids can be
hepatotoxic. Prolonged or high exposure may result in
liver damage. In rare instances life-threatening
dysfunction may develop. It is advisable to visit a
physician periodically during each cycle to monitor liver
function and overall health. Intake of c17-alpha alkylated
steroids is commonly limited to 6-8 weeks, in an effort to
avoid escalating liver strain.
The use of a liver detoxification supplement such as Liver
Stabil, Liv-52, or Essentiale Forte is advised while taking
any hepatotoxic anabolic/androgenic steroids.
Side Effects (Cardiovascular):
Anabolic/androgenic steroids can have deleterious effects
on serum cholesterol. This includes a tendency to reduce
HDL (good) cholesterol values and increase LDL (bad)
cholesterol values, which may shift the HDL to LDL
balance in a direction that favors greater risk of
arteriosclerosis. The relative impact of an
anabolic/androgenic steroid on serum lipids is dependant
on the dose, route of administration (oral vs. injectable),
type of steroid (aromatizable or non-aromatizable), and
level of resistance to hepatic metabolism.
Methepitiostane has a strong effect on the hepatic
management of cholesterol due to its structural resistance
to liver breakdown, non-aromatizable nature, and route of
administration. Anabolic/androgenic steroids may also
adversely affect blood pressure and triglycerides, reduce
endothelial relaxation, and support left ventricular
hypertrophy, all potentially increasing the risk of
cardiovascular disease and myocardial infarction.
To help reduce cardiovascular strain it is advised to
maintain an active cardiovascular exercise program and
minimize the intake of saturated fats, cholesterol, and
simple carbohydrates at all times during active AAS
administration. Supplementing with fish oils (4 grams per
day) and a natural cholesterol/antioxidant formula such as
Lipid Stabil or a product with comparable ingredients is
also recommended.
Side Effects (Testosterone Suppression):
All anabolic/androgenic steroids when taken in doses
sufficient to promote muscle gain are expected to
suppress endogenous testosterone production. Without
the intervention of testosterone stimulating substances,
testosterone levels should return to normal within 1-4
months of drug secession. Note that prolonged
hypogonadotrophic hypogonadism can develop
secondary to steroid abuse, necessitating medical
intervention.
The above side effects are not inclusive. For more detailed
discussion ofpotential side effects, see the Steroid Side Effects
section of this book.
Administration (Men):
Methepitiostane was never approved for use in humans.
Prescribing guidelines are unavailable. An effective
dosage for physique- or performance-enhancing
purposes falls in the range of 10-20 mg daily.This is usually
taken for no longer than 6-8 weeks, in an effort to avoid
significant liver strain. At this level the drug should impart
a measurable but moderate lean-mass-building effect,
which, depending on dietary and metabolic factors, may
be accompanied by measurable fat loss and an increase in
definition. Doses of 30 mg per day are also commonly
used, however given the high relative potency of the steroid may present significant hepatotoxicity. When
administered, higher doses are usually taken for durations
lasting no longer than 4-6 weeks.
Administration (Women):
Methepitiostane was never approved for use in humans.
Prescribing guidelines are unavailable. An effective
dosage for physique- or performance-enhancing
purposes would be around 5 mg per day. This would be
taken for no longer than 4-6 weeks, in an effort to avoid
significant liver strain or virilizing side effects. Given that
complete separation of anabolic and androgenic effect
has not been achieved with any steroid, this agent is still
capable of producing virilizing activity given the right
dose or individual sensitivity.
Availability:
Methepitiostane is currently only produced in U.S. as a
sports nutrition product, sold as Havoc and under
numerous other brand names.
